Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 16 January, 2020

Northern Trust Corp

Form 8.3 - Abbvie Inc

RNS Number : 0765A
Northern Trust Corporation
16 January 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

 Northern Trust Corporation

Company dealt in

 AbbVie Inc

Class of relevant security to which the dealings being disclosed relate (Note 2)

 Common Stock USD 0.01

of dealing

 15th January  2020

 

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

 

 

 

(1) Relevant securities

 21,622,571   1.46% *

 

Derivatives than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 21,622,571   1.46% *

 

             

 

* Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 81 securities into the relevant accounts and 673,103 securities out of the relevant accounts.

 

                                                                                                                                                                                                 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

 

 

(1) Relevant securities

 

 

 

Derivatives than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

Ap20

 

1.       DEALINGS (Note 4)  *

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit ($)

SELL

353

88.76

BUY

538

89.26

BUY

59

89.26

BUY

16336

89.26

BUY

1778

89.26

BUY

60

89.26

BUY

552

89.26

BUY

244

89.26

BUY

26

89.26

SELL

17670

89.26

BUY

972

88.77

SELL

1193

89.83

SELL

8105

89.26

BUY

308

89.36

BUY

55

89.26

BUY

3

89.1317

BUY

18

89.1317

BUY

5

89.1317

SELL

110

89.26

BUY

4

89.1317

BUY

10

89.1317

BUY

11

89.26

BUY

8

89.26

BUY

12

89.1317

BUY

5

89.1317

BUY

4

89.1317

SELL

285

89.26

BUY

9

89.1317

BUY

8

89.1317

BUY

8

89.1317

SELL

4

89.03

BUY

4

89.1317

BUY

5

89.1317

BUY

3

89.1317

BUY

41

89.1317

BUY

14

89.1317

SELL

20

89.14

BUY

28

89.26

BUY

4

89.1317

BUY

14

89.26

BUY

72

89.1317

SELL

391

89.6

SELL

40

89.85

SELL

29

89.543

SELL

50

88.77

SELL

32

89.08

BUY

943

88.96

SELL

101

88.945

SELL

20

88.95

SELL

800

89.089

SELL

20

89.15

SELL

50

89.44

BUY

11

88.86

BUY

32

88.86

 

 

 

 

 

                           

(b)      Derivatives transactions (other than options transactions)

 

Product name,

CFD

Nature of transaction

6)

Number of relevant securities

7)

Price per unit

5)

 

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

of transaction

8)

per unit

 

 

 

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.

 

 

  

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

 16th January 2020

Contact name

 Frances McIlrath

Telephone number

 3535717287

If a connected EFM, name of offeree/offeror with which connected

 

 

If a connected EFM, state nature of connection (Note 10)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEBFMATMTMBBAM

a d v e r t i s e m e n t